We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

16 hedge funds and large institutions have $54.8K invested in Sonoma Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

33% more funds holding

Funds holding: 12 → 16 (+4)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.01% less ownership

Funds ownership: 0.12% → 0.11% (-0.01%)

44% less capital invested

Capital invested by funds: $97.3K → $54.8K (-$42.5K)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$37.2K
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.5K
3
Millennium Management
Millennium Management
New York
+$10.2K
4
HF
HRT Financial
New York
+$8.88K
5
Goldman Sachs
Goldman Sachs
New York
+$3.23K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$29.7K
2
Renaissance Technologies
Renaissance Technologies
New York
-$11K
3
BlackRock
BlackRock
New York
-$198
4
Osaic Holdings
Osaic Holdings
Arizona
-$38
5
TRCT
Tower Research Capital (TRC)
New York
-$6
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$21.1K +$37.2K +5,839 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$6.45K – – –
JP Morgan Chase
3
JP Morgan Chase
New York
$5.96K +$10.5K +1,652 New
Millennium Management
4
Millennium Management
New York
$5.75K +$10.2K +1,595 New
HF
5
HRT Financial
New York
$5K +$8.88K +1,393 New
State Street
6
State Street
Massachusetts
$4.39K – – –
Goldman Sachs
7
Goldman Sachs
New York
$1.82K +$3.23K +506 New
TRCT
8
Tower Research Capital (TRC)
New York
$1.71K -$6 -1 -0.2%
UBS Group
9
UBS Group
Switzerland
$1.61K +$2.85K +447 New
ASN
10
Advisory Services Network
Georgia
$444 +$784 +123 New
BlackRock
11
BlackRock
New York
$409 -$198 -31 -22%
US Bancorp
12
US Bancorp
Minnesota
$90 – – –
Morgan Stanley
13
Morgan Stanley
New York
$32 +$32 +5 +125%
Wells Fargo
14
Wells Fargo
California
$19 +$19 +3 +150%
AF
15
Allworth Financial
California
$12 – – –
Bank of America
16
Bank of America
North Carolina
$8 – – –
TSS
17
Two Sigma Securities
New York
– -$29.7K -1,926 Closed
Renaissance Technologies
18
Renaissance Technologies
New York
– -$11K -700 Closed
Osaic Holdings
19
Osaic Holdings
Arizona
– -$38 -3 Closed

SNOA Hedge Fund Activity: Q4 2023 in Review

16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2023, worth a combined $54.8K — down 44% from $97.3K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new SNOA positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $37.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29.7K sold.

  • 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2023, up from 12 in Q3 2023.
  • Funds reported $54.8K of Sonoma Pharmaceuticals stock for Q4 2023, down 44% quarter-over-quarter.
  • 7 funds opened new Sonoma Pharmaceuticals positions in Q4 2023 and 3 closed out, a net change of +4 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q4 2023 was Citadel Advisors, an estimated $37.2K added.
  • The largest Sonoma Pharmaceuticals seller in Q4 2023 was Two Sigma Securities, an estimated $29.7K sold.

Based on aggregated 13F filings for Q4 2023.